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Krüppel-like factor 4 (Klf4) is a transcription factor involved
in differentiation and proliferation inmultiple tissues.We dem-
onstrated previously that tamoxifen-induced deletion of the
Klf4 gene inmice accelerated neointimal formation but delayed
down-regulation of smooth muscle cell differentiation markers
in carotid arteries following injury. To further determine the
role of Klf4 in the cardiovascular system, we herein derived
mice deficient for the Klf4 gene in smooth and cardiac muscle
using the SM22 promoter (SM22-CreKI/Klf4loxP/loxPmice).
SM22-CreKI/Klf4loxP/loxP mice were born at the expected
Mendelian ratio, but they gradually died after birth. Although
40% of SM22-CreKI/Klf4loxP/loxP mice survived beyond
postnatal day 28, they exhibited marked growth retardation.
In wild-type mice, Klf4 was expressed in the heart from late
embryonic development through adulthood, whereas it was
not expressed in smooth muscle. No changes were observed in
morphology or expression of smoothmuscle cell differentiation
markers in vessels of SM22-CreKI/Klf4loxP/loxP mice. Of
interest, cardiac output was significantly decreased in SM22-
CreKI/Klf4loxP/loxPmice, as determinedbymagnetic resonance
imaging. Moreover, a lack of Klf4 in the heart resulted in the
reduction in expression of multiple cardiac genes, including
Gata4. In vivo chromatin immunoprecipitation assays on the
heart revealed that Klf4 bound to the promoter region of the
Gata4 gene. Results provide novel evidence that Klf4 plays a key
role in late fetal and/or postnatal cardiac development.
Krüppel-like factor 4 (Klf4)2 (formerly known as gut-en-
riched Krüppel-like factor or GKLF) is a zinc finger transcrip-
tion factor involved in both the regulation of differentiation
and proliferation in multiple cell types. For example, Klf4 is
required for terminal differentiation of the skin (1). Conven-
tional Klf4 knock-out mice are born at the expectedMendelian
ratio but die within 15 h after birth due to a failure of normal
basement membrane formation. Klf4 knock-out mice also
exhibit a 90% decrease in the number of goblet cells in the
colon, and the remaining goblet cells are histologically and
ultrastructurally abnormal (2). Tissue-specific ablation of Klf4
in mouse stomach results in increased proliferation and altered
differentiation of the gastric epithelia (3). In the eye, conditional
knock-out of Klf4 results in abnormal corneal epithelium and
lack of goblet cells in the conjunctiva (4). As such, Klf4 is impli-
cated in a variety of cellular differentiation and proliferation
processes by activating or repressing transcriptional activity of
multiple genes. Interest in Klf4 also has increased dramatically
over the past year based on observations that it is one of four
factors (Oct3/4, Sox2, Klf4, and c-Myc) that, in combination,
can induce a variety of somatic cells into an embryonic stem
cell-like state or induced pluripotent stem cells (5, 6).
Klf4 also plays a key role in the regulation of gene transcrip-
tion in the cardiovascular system.We have shown that Klf4 is a
potent repressor of multiple smooth muscle cell (SMC) differ-
entiationmarker genes, including SM (smoothmuscle) -actin
(Acta2), SM-myosin heavy chain (Myh11), and SM22 (7–9).
Indeed, Klf4 binds to the promoter-enhancer regions of SMC
differentiation marker genes and mediates platelet-derived
growth factor BB or oxidized phospholipid-induced suppres-
sion of these genes in cultured SMCs (7, 9–11). Although Klf4
normally is not expressed in differentiated SMCs in vivo, it is
transiently induced in phenotypically modulated SMCs after
vascular injury (9, 12). Of significant importance, we recently
demonstrated that conditional deletion of theKlf4 gene inmice
results in transient delays in down-regulation of SMC differen-
tiation markers, but subsequent SMC hyperproliferation and
enhanced neointimal formation following carotid ligation
injury (12). In addition, we presented evidence that enhanced
neointimal formation in Klf4-deficient mice was caused by
reduced induction of p21WAF1/Cip1, a cell-cycle inhibitor, in
SMCs following injury. Klf4 has also been shown to be
expressed in vascular endothelial cells.Hamik et al. (13) showed
that overexpression ofKlf4 increased expression of anti-inflam-
matory and antithrombotic factors, including eNOS and
thrombomodulin, whereas knockdown of Klf4 led to enhance-
ment of tumor necrosis factor-induced expression of vascular
cell adhesionmolecule-1 and tissue factor in cultured endothe-
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lial cells. As such, results of the preceding studies provide evi-
dence that Klf4 is a critical factor regulating gene transcription
in a variety of vascular cells. However, as yet, no studies have
examined its function in the heart either in vivo or in vitro.
Recently, mice expressing Cre recombinase under the con-
trol of the SM22 promoter (SM22-CreKI mice) have
been developed by knocking-in the Cre recombinase-coding
sequence into the SM22 gene locus via homologous recombi-
nation (14). SM22 is a marker of SMCs, but it also is tran-
siently expressed in the heart between embryonic days (E) 8.0
and 12.5 (15). Therefore, SM22-CreKI mice exhibit Cre
recombination in a smooth and cardiac muscle-specific man-
ner but only after these cells have initiated differentiation. To
further determine the role of Klf4 in the cardiovascular system,
we herein derived smooth and cardiac muscle-specific condi-
tional Klf4-deficient mice by breeding SM22-CreKI mice
with mice carrying a loxP allele of Klf4 (Klf4loxP mice) (2) and
analyzed their phenotype.
EXPERIMENTAL PROCEDURES
Generation of Smooth and CardiacMuscle-specific Klf4-defi-
cientMice—Animal protocols were approved by the University
of Virginia Animal Care and Use Committee. Klf4loxP mice
were provided by Dr. Klaus H. Kaestner (University of Penn-
sylvania) (2). The Klf4 gene consists of four exons, (see Fig.
1A) and exon 1 only encodes a first methionine codon. In
Klf4loxP mice, recombination of the Klf4loxP allele deletes
exons 2 and 3 and causes a frameshift mutation in exon 4,
which abolishes Klf4 function completely (2, 12). Klf4loxP
mice were bred with transgenic mice expressing Cre recom-
binase under the control of the SM22 promoter (SM22-
CreKI mice) (14) to generate smooth and cardiac muscle-
specific Klf4-deficient mice. Indeed, male heterozygous
SM22-CreKI mice were bred with female Klf4loxP/loxP
mice to generate SM22-CreKI/Klf4loxP/wt mice. Male or
female SM22-CreKI/Klf4loxP/wt mice were then crossed
with female or male Klf4loxP/loxP mice to generate SM22-
CreKI/Klf4loxP/loxP mice (smooth and cardiac-specific
Klf4-deficient mice) and SM22-CreKI/Klf4loxP/loxP mice
(control mice). Both Klf4loxP mice and SM22-CreKI mice
were mixed background strains of C57BL/6 and 129, and
littermates were used for all comparisons. Genotyping for
the Klf4 floxed locus was performed by PCR using three
primers, as described previously (2, 12).
Histology, Immunohistochemistry, and Immunofluorescence—
Embryos and multiple tissues were harvested, fixed, and
embedded into paraffin as described previously (16). The
5-m sections were prepared and stained with antibodies for
Klf4 (11) or Ki-67 (Santa Cruz Biotechnology, Santa Cruz,
CA). Staining was visualized by diaminobenzidine (DAB)
and counterstained with hematoxylin. Klf4 staining in the
skin was visualized by DAB and counterstained with azure B.
TUNEL staining was performed according to the manufac-
turer’s instructions (Roche Diagnostics) (12). Dual immuno-
fluorescence studies were performed with Klf4 antibody
raised in rabbit (11) and Gata4 antibody raised in goat (Santa
Cruz Biotechnology) (17). Specific staining was detected by
Alexa Fluor 555-conjugated anti-rabbit antibody (Invitro-
gen) and Alexa Fluor 488-conjugated anti-goat antibody
(Invitrogen). Sectionswerecounterstainedwith4,6-diamidino-2-
phenylindole. Formorphological analysis, sectionswere subjected
to Russell-Movat pentachrome staining.
Electron Microscopy—Mice were sacrificed by isoflurane
overdose followed by cervical dislocation. The beating hearts
were quickly removed and rinsed in oxygenated Krebs buffer
with 30 mmol/liter 2,3-butanedione monoxime at 37 °C. The
hearts were perfused through the aorta with 2% glutaraldehyde
and kept in 2% glutaraldehyde overnight at 4 °C. Small pieces
(1-mm in diameter) of the lower left ventricle were then post-
fixed, stained, and embedded following the standard procedure
(18, 19): 2% osmium tetroxide for 2 h, saturated aqueous uranyl
acetate for 1.5 h, dehydrated in a series of graded alcohols, and
embedded in Spurr’s resin. Sections were poststained by lead
citrate and imaged in a Philips CM12 electron microscope at
120 KeV equipped with a SIA 8C 2,000  3,000 CCD camera
(Duluth, GA).
Vascular Casting—Pregnant mice 18.5 days post coitus were
euthanized by cervical dislocation under isoflurane anesthesia.
Embryos were isolated and rinsed in phosphate-buffered saline
at 37 °C. The umbilical vein was cut to allow the wash out of
blood from the circulation system. Prior to injecting the casting
medium, embryos were perfused with 1 ml of warmed 1% lido-
caine hydrochloride in 0.9% NaCl containing 1 units/ml hepa-
rin via the umbilical artery. Perfusatewas injected until the fluid
that flowed out from umbilical vein was clear. The vasculature
was then fixed for 5 min using 1 ml of warmed 4% paraformal-
dehyde in phosphate-buffered saline. 1 mm of casting material,
Baston’s No. 17 (Polysciences) supplemented with jet acrylic
liquid (LangDentalManufacturing Co., Inc.), was then injected
via the umbilical artery. The umbilical cord was tied, and
embryos were stored at 4 °C for 12 h to allow poly-
merization of the casting material. Tissues were then dissolved
in 7 mol/liter KOH, and the circulatory cast was cleaned using
forceps.
Cardiac Magnetic Resonance Imaging (MRI)—Cardiac MRI
was performed in Department of Radiology at the University
of Virginia, as previously described (20). Briefly, a 4.7-Tesla
MRI system (Varian 200/400 Inova) withMagnex gradients (80
G/cm maximum strength) was used with a custom built Litz
radiofrequency coil (Doty Scientific, Columbia, SC).Anesthesia
was induced with 3% isoflurane and was maintained with a 1%
isoflurane-oxygen mixture throughout the study. Core body
temperature wasmaintained at 37.0 0.1 °C by using an exter-
nal water bath. Electrocardiogram (ECG) triggering was
achieved with a gating/monitoring system (SA Instruments,
Stony Brook, NY). Contiguous short-axis bright blood cine
images of the left ventricle were obtained with a two-dimen-
sional FLASH gradient echo sequence. Images were analyzed
with ARGUS image analysis software (Siemens Medical Solu-
tions, Princeton, NJ).
Microarray and Gene Ontology Analysis—Microarray analy-
sis was performed in quadruplicate by SA Biosciences (Fred-
erick,MD) using Agilent wholemouse genome oligonucleotide
microarray kit (Agilent Technologies, Santa Clara, CA). Gene
ontology analysis with PANTHER (21) was performed using
the database for annotation, visualization, and integrated dis-
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covery 2008 (DAVID). Genes considered dysregulated were
those with p values  0.02.
Real-time RT-PCR—Total RNA prepared from the mouse
heart, skeletal muscle, brain, and aorta was used for real-time
RT-PCR. Primer and probe sequences for Klf4 and 18S rRNA
were described previously (9, 17). Primer and probe sequences
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vivo quantitative ChIP assays were
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amplify the promoter region of the
Gata4 gene or the c-fos gene (22).
Primer sequences for the Gata4





presented as mean  S.E. Unless
mentioned, statistical analyses were
performed by one-way analysis of
variance with a post hoc Fisher pro-
tected least significant difference
test or unpaired t test. p values 
0.05 were considered significant.
RESULTS
Smooth and Cardiac Muscle-spe-
cific Deletion of the Klf4 Gene Was
Associated with Marked Postnatal
Death and Growth Retardation—
To generate smooth and cardiac
muscle-specificKlf4-deficient mice,
we used a two-step breeding protocol. First, heterozygous
SM22-CreKI mice were bred with Klf4loxP/loxP mice to gen-
erate SM22-CreKI/Klf4loxP/wt mice. SM22-CreKI/
Klf4loxP/wt mice were then crossed with Klf4loxP/loxP mice to
generate SM22-CreKI/Klf4loxP/loxP mice and SM22-
CreKI/Klf4loxP/loxP mice. SM22-CreKI/Klf4loxP/loxP mice
were smooth and cardiacmuscle-specificKlf4-knock-outmice,
whereas SM22-CreKI/Klf4loxP/loxP mice served as controls
(Fig. 1A). As shown in Fig. 1B, both SM22-CreKI/
Klf4loxP/loxP mice and control mice were born at the expected
Mendelian ratio and could not be distinguished from one
another at birth (Fig. 1D). However, SM22-CreKI/
Klf4loxP/loxP mice gradually died after birth, and only 40% sur-
vived beyond postnatal day (P)28 (Fig. 1C). In addition, the
remaining SM22-CreKI/Klf4loxP/loxPmice were significantly
smaller than their control littermates, a phenotype observed in
100% of surviving SM22-CreKI/Klf4loxP/loxP mice (Fig. 1E).
At P28, the body weight of SM22-CreKI/Klf4loxP/loxP mice
was 7.3 0.6 g, whereas controlmice weighed 12.0 0.4 g (Fig.
1F). SM22-CreKI/Klf4loxP/loxP mice also exhibited shorter
tails (2.6  0.7 cm versus 7.0  0.1 cm in control mice at P28,
FIGURE 1. Smooth and cardiac muscle-specific deletion of the Klf4 gene was associated with significant
postnatal death and growth retardation. A, a schematic representation of smooth and cardiac muscle-
specific deletion of the Klf4 gene is shown. The numbers shown represent Klf4 exons. Triangles represent the
loxP sites. X, breeding. B, the genotype of 191 offspring from the breeding between SM22-CreKI (CreKI)/
Klf4loxP/wt mice and SM22-CreKI/Klf4loxP/loxP mice was examined by PCR at the time of birth. C, Kaplan-Meier
survival curves for SM22-CreKI/Klf4loxP/loxP, SM22-CreKI/Klf4loxP/wt, SM22-CreKI/Klf4loxP/loxP, and SM22-
CreKI/Klf4loxP/wt mice are shown (n  36 per each genotype). A log-rank test for trend yielded. *, p  0.05. D and
E, representative pictures of SM22-CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P1 (D) and P28 (E)
are shown. F, changes in the body weight of SM22-CreKI/Klf4loxP/loxP, SM22-CreKI/Klf4loxP/wt, SM22-
CreKI/Klf4loxP/loxP, and SM22-CreKI/Klf4loxP/wt mice after birth are shown (n  2025 per each genotype). *,
p  0.05 compared with other genotypes. Docta represent the mean  S.E.
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p  0.05) and partial hair loss on their backs, although it is
unclear whether the latter changes are a function of Klf4 loss
per se or results from competition with their full-sized litter-
mates. In summary, results clearly indicate that loss of Klf4 in
smooth and/or cardiac muscle is associated with a major phe-
notype during the postnatal period.
Klf4 Was Expressed in the Heart from Late Embryonic Devel-
opment to Adulthood—To elucidate mechanisms responsible
for the postnatal phenotype of conditional Klf4 knock-out
mice,we first examinedwhetherKlf4was expressed in the heart
and SMCs during normal development and whether the
Klf4loxP allele was recombined in a tissue-specific manner in
conditionalKlf4 knock-outmice. Klf4 expression patterns were
determined in wild-type mice by immunohistochemistry. As
shown in Fig. 2,A–C and supplemental Fig. I,A–C, Klf4 was not
expressed in the heart at E9.5, E11.5, and E15.5. However, Klf4
was expressed at E18.5 in both the atrium and the ventricle of
the heart and was also expressed in
P1 and adult hearts (Fig. 2,D–F and
supplemental Fig. I, D and E). Of
note, Klf4 expression was seen in
nearly 50% of the cells in the heart.
To determine which cells express
Klf4 in the heart, we tested colocal-
ization of Klf4 and Gata4, which is
mainly expressed in cardiomyocytes
(23). Results of dual immunofluo-
rescence studies showed that Klf4
and Gata4 were coexpressed in the
heart, although some of Klf4-posi-
tive cells were negative for Gata4
(Fig. 2G). In contrast to the expres-
sion of Klf4 in the heart, Klf4 was
not detectable in SMCs in any SMC-
containing tissues examined during
embryonic development or in the
adult. For example, it was not
expressed in the third, fourth, and
sixth branchial arch arteries and the
dorsal aorta at E11.5 (Fig. 2B).
Moreover, it was not expressed in
SMCs of the aorta, the stomach, and
the bladder as well as in the skeletal
muscle in the adult (Fig. 2, H–K),
although it was expressed in aortic
endothelial cells, some adventitial
cells in the aorta, and epithelial cells
in the stomach.
Recombination of the Klf4loxP
allele was examined in SM22-
CreKI/Klf4loxP/loxP mice and con-
trol mice. As shown in Fig. 3A, the
Klf4loxP allele was efficiently recom-
bined in the heart of SM22-
CreKI/Klf4loxP/loxP mice. The
Klf4loxP allele was also recombined
in the colon, which contains a large
fraction of SMCs, whereas little
recombination was observed in the brain of SM22-CreKI/
Klf4loxP/loxP mice. Deletion of Klf4 was examined at both the
mRNA and protein levels. Klf4 mRNA expression was
decreased in the heart of SM22-CreKI/Klf4loxP/loxP mice,
although it was low and unaffected in the skeletal muscle and
the brain (Fig. 3B). Moreover, Klf4 protein expression was dra-
matically decreased in the heart, whereas it was unaltered in
epithelial cells of the skin and colon in SM22-CreKI/
Klf4loxP/loxP mice (Fig. 3C). Collectively, these results indicate
that Klf4 is expressed in the heart but not in SMCs from late
embryonic development to adulthood and that loss of Klf4 in
the heart, rather than in SMCs, is likely to be responsible for the
phenotype of SM22-CreKI/Klf4loxP/loxP mice.
SM22-CreKI/Klf4
loxP/loxP
Mice Had No Discernible Changes
in SMC Differentiation or Vascular Morphology—Although
Klf4 was not expressed in SMCs during normal development,
we analyzed multiple vascular parameters to determine
FIGURE 2. Klf4 was expressed in the heart from late embryonic development to adulthood. A–F, Klf4
expression was determined by immunohistochemistry in wild-type embryos at E9.5 (A), at E11.5 (B), at E15.5 (C),
and at E18.5 (D), as well as in the heart of wild-type neonates at P1 (E) and adult (F). Klf4 expression was
visualized by DAB, and sections were counterstained with hematoxylin. Bars for A–C, 100 m; D–F, 50 m. H,
heart; DA, dorsal aorta; III, third branchial arch artery; IV, fourth branchial arch artery; VI, sixth branchial arch
artery. G, colocalization of Klf4 and Gata4 in the heart of wild-type mice was examined by dual immunofluo-
rescence staining. Klf4 staining was visualized by Alexa Fluor 555 (red), and Gata4 staining was visualized by
Alexa Fluor 488 (green). Sections were counterstained with 4,6-diamidino-2-phenylindole (blue). Arrowheads
indicate cells coexpressing Klf4 and Gata4. Bar, 50 m. H–K, Klf4 expression was examined in the aorta (H), the
skeletal muscle (I), the stomach (J), and the bladder (K) of wild-type mice. Arrowheads indicate aortic endothe-
lial cells (H) and gastric epithelial cells (J), which express Klf4. SM, smooth muscle layer. Bars for H and I, 50 m;
bars for J and K, 100 m. Representative pictures are shown.
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whether defects in SMCsmight have contributed to the overall
phenotype of SM22-CreKI/Klf4loxP/loxP mice. First, we
examined the overall morphology of the aorta. Themedial area
of the thoracic aorta was not different between SM22-
CreKI/Klf4loxP/loxP and control mice, and no neointima was
found in either mice (Fig. 4,A and B). Second, expression of the
SMC differentiation markers, Acta2 andMyh11, was unaltered
in the aorta of SM22-CreKI/Klf4loxP/loxP mice (Fig. 4C).
Third, the morphology of smaller arteries including the coro-
nary arteries and the renal arteries was examined, but no differ-
ences were found between SM22-CreKI/Klf4loxP/loxP and
control mice (Fig. 4D and data not shown). Finally, develop-
ment of coronary arterieswas examined in E18.5 embryos using
vascular casting (Fig. 4E). No differences in the pattern of for-
mation of coronary arteries were observed between SM22-
CreKI/Klf4loxP/loxP and control mice. Taken together, these
results and the results showing no Klf4 expression in SMCs
during normal development (Fig. 2) indicate that the phenotype
of SM22-CreKI/Klf4loxP/loxPmice was unlikely to be second-
ary to vascular defects.
Cardiac OutputWas Decreased in SM22-CreKI/Klf4
loxP/loxP
Mice—We next ascertained whether there was a cardiac phe-
notype in SM22-CreKI/Klf4loxP/loxP mice. First, serial histo-
logical sections of the heart were analyzed in ten SM22-
CreKI/Klf4loxP/loxP mice and six control mice, including four
SM22-CreKI/Klf4loxP/loxPmice that died before P28 because
they might have more serious cardiac phenotype than the sur-
vivingmice (Fig. 5A). No anatomical andmorphological abnor-
malities were found in the heart and the great arteries of
SM22-CreKI/Klf4loxP/loxP mice.
Heart weight was measured at P14
and P28. Although the heart weight
itself was slightly decreased in
SM22-CreKI/Klf4loxP/loxP mice
(48 3mg at P14, 66 7mg at P28)
than control mice (54  2 mg at
P14, 82  2 mg at P28), the ratio of
heart to body weight was significan-
tly increased in SM22-CreKI/
Klf4loxP/loxP mice (7.8  0.2 mg/g at
P14, 7.5  0.4 mg/g at P28) than
control mice (6.7 0.3 mg/g at P14,
5.6  0.1 mg/g at P28) (Fig. 5, B and
C). To determine whether these dif-
ferences were due to altered rates of
proliferation or apoptosis, Ki-67
staining and TUNEL staining were
performed in the heart at P28. The
ratio of Ki-67 positive cells was
not different between SM22-
CreKI/Klf4loxP/loxP (5.0  0.6 per
field) and control (4.4  0.5 per
field) mice (Fig. 5D). The ratio of
TUNEL-positive cells was also not
different between SM22-CreKI/
Klf4loxP/loxP (2.8  0.2 per field) and
control (2.6  0.3 per field) mice
(Fig. 5E). In addition, the rates of
proliferation and apoptosis in the heart were not different
between SM22-CreKI/Klf4loxP/loxP versus control mouse
embryos at E18.5 (supplemental Fig. II). Moreover, we did not
detect any substantial differences in the ultrastructure of car-
diomyocytes between the two groups, as determined by elec-
tron microscopy (supplemental Fig. III). These results suggest
that SM22-CreKI/Klf4loxP/loxP mice do not exhibit either an
altered proliferation rate or apoptotic rate in the heart and that
the alteration in the ratio of heart to body weight is mainly due
to the reduced body weight of SM22-CreKI/Klf4loxP/loxP
mice.
Cardiac function was analyzed in SM22-CreKI/
Klf4loxP/loxP and control mice by MRI (Table 1 and
supplemental Fig. IV). 5-week-old mice were analyzed because
they were the minimum size for cardiac MRI. Consistent with
the heart weight measured in Fig. 4C, the left ventricular mass
of SM22-CreKI/Klf4loxP/loxP mice (40.0  2.3 mg) was
smaller than controls (43.0  2.0 mg). Of interest, both the
ejection fraction (EF) and the heart rate (HR) were significantly
decreased in SM22-CreKI/Klf4loxP/loxP mice (EF, 53.8 
2.6%; HR, 394  25 beats/min), as compared with control
mice (EF, 66.2  1.9%; HR, 441  23 beats/min). No cardiac
arrhythmia was found in SM22-CreKI/Klf4loxP/loxP mice
(supplemental Fig. V). The decreases in these parameters (EF
and HR) resulted in a profound reduction in cardiac output
(7.5  0.2 l/min in SM22-CreKI/Klf4loxP/loxP mice versus
9.7  0.6 l/min in control mice). It is well established that
decreased cardiac output is associated with abnormal postnatal
growth (24, 25). Therefore, results of cardiac MRI suggest that
FIGURE 3. SM22-CreKI/Klf4loxP/loxP mice exhibited selective loss of Klf4 expression in the heart. A, dele-
tion of the Klf4loxP allele was tested in multiple tissues including the heart, the colon, and the brain of SM22-
CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P28, as determined by PCR (n  3 per each genotype).
B, expression of Klf4 mRNA was examined by real-time RT-PCR in the heart, the skeletal muscle (sk. m), and the
brain of SM22-CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P28 (n  6 per each genotype). C, Klf4
expression was examined by immunohistochemistry in the skin, the colon, and the heart of SM22-CreKI/
Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P28. Klf4 was visualized by DAB, and sections were counter-
stained with azure B for the skin or with hematoxylin for the colon and the heart. Representative pictures are
shown (n  4 per each genotype). Bars, 100 m for upper panels; 50 m for lower panels.
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the growth retardation and partial postnatal death in SM22-
CreKI/Klf4loxP/loxPmice are caused, at least in part, by cardiac
insufficiency, although we did not notice obvious signs of heart
failure, such as lung edema in SM22-CreKI/Klf4loxP/loxP
mice.
Loss of Klf4 Resulted inDecreased Expression ofMultiple Car-
diac Genes—To determine the molecular mechanisms for
decreased cardiac output in SM22-CreKI/Klf4loxP/loxP mice,
microarray analyses were performed on hearts of SM22-
CreKI/Klf4loxP/loxP and control mice at P14. Consistent with
results of previous studies showing that Klf4 is both an activator
and a repressor of gene transcription (26), results of microarray
analyses showed that a large number of genes were increased or
decreased by Klf4 deletion (Fig. 6A). Indeed, 244 genes were
increased 	3-fold, whereas 183 genes were decreased 	3-fold
in the heart of SM22-CreKI/Klf4loxP/loxPmice. A gene ontol-
ogy analysis of these dysregulated transcripts revealed that the
most significantly enriched genes participate in cation trans-
port and that genes related to proteolysis andmRNA transcrip-
tional regulation were also affected
(Fig. 6B). Of major interest, loss of
Klf4 was associated with coordinate
down-regulation of a number of
cardiac genes includingMyl1 (myo-
sin light polypeptide 1, also known
as cardiac myosin light chain),
Tnnc1 (cardiac/slow skeletal tropo-
nin C), Mybpc2 (myosin binding
protein C), Nppb (natriuretic pep-
tide precursor type B, also known as
brain natriuretic peptide), and
Gata4 (supplemental Table 1). Real-
time RT-PCR analysis also showed
that multiple cardiac genes includ-
ing Nppa (natriuretic peptide pre-
cursor type A, also known as atrial
natriuretic factor), Nppb, Actc1
(cardiac -actin), Myh7 (myosin
heavy chain 7, also known as -my-
osin heavy chain), Serca2 (sarco-
plasmic/endoplasmic reticulum
Ca(2) pump gene 2), and Gata4
were dramatically decreased in
the heart of SM22-CreKI/
Klf4loxP/loxP mice (Fig. 6C). Expres-
sion of these genes was not
decreased in the heart of SM22-
CreKI/Klf4loxP/wt mice, suggesting
that loss of one Klf4 allele is insuffi-
cient to induce similar changes and
that changes are not the conse-
quence of loss of one SM22 allele
due to insertion of the Cre recombi-
nase gene. Reduction of expression
of cardiac myosin light chain and
Gata4 in Klf4-deficient mice was
also detectable by Western blotting
(Fig. 6D). Taken together, these
results suggest that cardiac loss of Klf4 causes a significant
decrease in expression of a number of cardiac genes required
for contractile function and such a decrease is likely to contrib-
ute to the decreased cardiac output in SM22-CreKI/
Klf4loxP/loxP mice.
In Vivo ChIP Assays Demonstrated Klf4 Binding to the Gata4
Promoter in Wild-type but Not Conditional Klf4 Knock-out
Mouse Hearts—Of the genes decreased by Klf4 deletion, Gata4
is known to be critical for regulating many cardiac genes (23).
We performed in vivo ChIP assays to determine whether Klf4
directly binds to the promoter region of the Gata4 gene in the
heart. Although little is known regarding the transcriptional
control of theGata4 gene, results of several studies showed that
multiple GC boxes and an E box within its promoter (Fig. 7A)
were important for expression (27–29). We found a consensus
Klf4 binding site at 125/119 bp, in close proximity to four
GC boxes and an E box (Fig. 7A). Indeed, the consensus Klf4
binding sequence is 5-(G/A)(G/A)GG(C/T)G(C/T)-3, which
is conserved between the mouse, rat, and human Gata4 pro-
FIGURE 4. SM22-CreKI/Klf4loxP/loxP mice had no differences in expression of SMC differentiation
marker genes or arterial structure as compared with control mice. A and B, the thoracic aorta from SM22-
CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P28 was perfused with 10% formalin under physio-
logical pressure and embedded into paraffin. Cross-sections were stained with Russell-Movat pentachrome
method (n  6 per each genotype). A, representative pictures are shown. Bars, 100 m. B, medial areas (the
average of three sections per each mouse) were measured using ImagePro software. C, expression of SMC
differentiation marker genes including Acta2 and Myh11 was examined by real-time RT-PCR in the aorta of
SM22-CreKI/Klf4loxP/loxP, SM22-CreKI/Klf4loxP/wt, and SM22-CreKI/Klf4loxP/loxP mice at P14 (n  5 per each
genotype). D, coronary arteries from SM22-CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P28 was
sectioned and stained with Russell-Movat pentachrome method (n  6 per each genotype). Representative
pictures of the left anterior descending artery are shown. Bars, 50 m. E, vascular casting of coronary arteries
from E18.5 embryos is shown. Bars, 1 mm.
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moter (30). Results of in vivo ChIP assays showed that Klf4 was
associated with theGata4 promoter region in the heart of con-
trol mice, whereas the binding was abolished in SM22-
CreKI/Klf4loxP/loxP mice (Fig. 7B and supplemental Fig. VI).
This binding was selective in that no Klf4 binding was detected
at the c-fos promoter. Results pro-
vide evidence that Klf4 regulates
Gata4 expression by binding to its
promoter region and suggest that
this is one of the mechanisms
whereby knock-out of cardiac Klf4
results in decreased expression of
multiple cardiac genes.
DISCUSSION
Results of the present studies
show that selective knock-out of the
Klf4 gene in smooth and cardiac
muscle is associated with significant
postnatal death and severe growth
retardation in surviving mice.
Moreover, we present several lines
of evidence that this phenotype is
primarily the result of loss of Klf4 in
the heart rather than in SMCs. First,
conditional Klf4-deficient mice
exhibited a marked decrease in car-
diac output and abnormal expres-
sion of a larger number of cardiac
genes required for its contractile
function including Myl1, Tnnc1,
Mybpc2, Actc1, Myh7, Serca2, and
Gata4. The decrease in cardiac out-
put was seen even in surviving
5-week-old Klf4-deficient mice.
Second, surprisingly, Klf4 was
highly expressed in the heart of
wild-type mice from late embryonic
development to adulthood, whereas
it was not detectable at all time
points examined in either vascular
or nonvascular SMCs. Third, results
of in vivo ChIP assays showed that
Klf4 directly bound to the Gata4
promoter region in the heart of con-
trol mice. Fourth, we found no dif-
ferences in the morphology or the overall structure of arteries
including the aorta, the coronary arteries, and renal arteries in
conditional Klf4 knock-out mice versus control mice. Finally,
there were no differences in the level of expression of SMC
differentiation marker genes in the aorta between these mice.
Taken together, results of the present studies provide the first
evidence thatKlf4 is a critical factor in cardiac development and
maturation.
In the present studies, we provide evidence that Klf4 regu-
lates Gata4 gene expression by binding to the consensus Klf4
binding site at 125/119 bp within the Gata4 promoter in
the postnatal heart. Gata4 is a zinc finger-containing transcrip-
tion factor that plays an essential role in promoting cardiac
development and differentiation of the myocardium, as well as
in regulating hypertrophic growth of the adult heart (23). It is
highly expressed in cardiomyocytes throughout embryonic
development, postnatal growth, and adulthood, duringwhich it
FIGURE 5. The rates of proliferation and apoptosis were unaltered in the hearts of SM22-CreKI/
Klf4loxP/loxP mice. A, hearts from SM22-CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P28 were
sectioned and stained with Russell-Movat pentachrome method. Representative pictures are shown (n  6 per
each genotype). Bars, 1 mm. B and C, heart weight and the ratio of heart to body weight were measured in
SM22-CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P14 and P28. *, p  0.05 compared with
SM22-CreKI/Klf4loxP/loxP mice. D and E, Ki-67 staining (D) and TUNEL staining (E) were performed in the heart
of SM22-CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P28 (n  5 per each genotype). Ki-67 stain-
ing was visualized by DAB, and sections were counterstained with hematoxylin. TUNEL staining was visualized
by fluorescein isothiocyanate, and sections were counterstained with 4,6-diamidino-2-phenylindole. Arrow-
heads indicate stained cells. Bars, 50 m.
TABLE 1
Structural and functional parameters of the heart in 5-week-old






Heart rate (beats/min) 441  23 394  25*
Left ventricular end diastolic volume (l) 33.5  1.8 33.8  3.1
Left ventricular end systolic volume (l) 11.5  1.2 15.7  1.9*
Stroke volume (l) 22.0  0.7 18.1  1.6*
Ejection fraction (%) 66.2  1.9 53.8  2.6*
Cardiac output (l/min) 9.7  0.6 7.5  0.2*
Left ventricular mass (mg) 43.0  2.0 40.0  2.3
*, p  0.05 compared with SM22-CreKI/Klf4loxP/loxP mice. n  5 per each
genotype.
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functions as a critical regulator of cardiac-specific gene expres-
sion. Despite these pivotal roles, little is known regarding the
factors and mechanisms for transcriptional regulation of the
Gata4 gene. Indeed, Heicklen-Klein and Evans (27) show that a
14.8-kb fragment upstreamof the transcription initiation site of
the Gata4 gene is required for its
expression in the heart of zebrafish.
Guittot et al. (28) show that the first
5-kb of Gata4 promoter-enhancer
sequence was sufficient to direct
gene expression in the adult mouse
heart, although they did not exam-
ine the activity of this fragment dur-
ing embryonic and postnatal devel-
opment. Recently, two GC boxes
and an E box between 124 bp and
36 bp of the mouse Gata4 pro-
moter have been shown to be
important for its expression during
differentiation of P19.CL6 cells into
beating cardiomyocyte-like cells in
vitro (29). Results of our present
studies showed that Klf4 selectively
bound to the Gata4 promoter
region in the heart of control mice
but not conditional Klf4 knock-out
mice, as determined by in vivo ChIP
assays. Although complete charac-
terization of the Gata4 promoter,
including promoter-reporter assays
and electrophoretic mobility shift
assays, will be required in further
studies, these results at least provide
novel evidence indicating that Klf4
plays an important role in regulating transcription of theGata4
gene. However, factors other thanKlf4 likely are responsible for
initial induction of Gata4 in the heart because Gata4 has been
shown to be expressed within these cells from a very early
embryonic time point (23), whereas we found that Klf4 was first
induced in the heart at E18.5. In addition, it also should be
noted that the phenotype of SM22-Cre/Klf4loxP/loxP mice
could not be explained solely by the reduction in Gata4 expres-
sion because results of previous studies showed that cardiac
muscle-specific Gata4 knock-out mice did not die after birth
(31). As numerous genes were dysregulated by Klf4 deletion,
multiplemechanisms, including the reduction inGata4 expres-
sion, would cooperatively contribute to the phenotype of
SM22-Cre/Klf4loxP/loxP mice.
Reduction in cardiac output is typically accompanied with
compensatory cardiac hypertrophy (24, 25). In the present
studies, however, smooth and cardiac muscle-specific Klf4-de-
ficient mice did not exhibit obvious cardiac hypertrophy.
Indeed, the heart weight of conditional Klf4 knock-out mice
was reduced as compared with that of control mice, whereas
the ratio of heart weight to body weight was reciprocally higher
in conditional Klf4 knock-out mice. In addition, the rates of
proliferation and apoptosis in the heart were not different
between the two groups. Lack of cardiac hypertrophy in Klf4-
deficient mice is probably caused by reduced expression of
Gata4 andother genes affected byKlf4deletion in thesemice. In
fact, results of previous studies showed that cardiac Gata4 is
required for hypertrophy, compensation, andmyocyte viability
as determined by analyses of cardiac-specific Gata4 knock-out
FIGURE 6. Multiple cardiac genes were decreased in the heart of SM22-CreKI/Klf4loxP/loxP mice. A and B,
microarray analysis was performed in the heart of SM22-CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP
mice at P14 (n  4 per each genotype). A, number of genes dysregulated by Klf4 deletion is shown by fold
change. B, the 427 genes increased or decreased 	3-fold by Klf4 deletion were subjected to gene ontology
analysis with PANTHER. Significantly enriched biological processes (p  0.03) are shown. Plotted is the log (p
value) with the threshold set to 1.5 [-log(0.03)]. C, expression of multiple cardiac genes including Nppa, Nppb,
Actc1, Myh7, Serca2, and Gata4 was examined by real-time RT-PCR in the heart of SM22-CreKI/Klf4loxP/loxP,
SM22-CreKI/Klf4loxP/wt, and SM22-CreKI/Klf4loxP/loxP mice at P14 (n  5 per each genotype). D, protein
expression of Klf4, cardiac myosin light chain (cMLC), Gata4, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was examined in the heart of SM22-CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P14 by
Western blotting. Representative pictures are shown (n  3 for each genotype).
FIGURE 7. Klf4 regulated Gata4 expression by binding to the Gata4 pro-
moter region. A, a schematic diagram of the Gata4 promoter is shown. A
consensus Klf4 binding site, 5-(G/A)(G/A)GG(C/T)G(C/T)-3, is located within
the Gata4 promoter, which contains 4 GC-rich elements and an E box. Num-
bers represent bp. B, association of Klf4 with the promoter regions of the
Gata4 gene and the c-fos gene was determined by in vivo ChIP assays in the
heart of SM22-CreKI/Klf4loxP/loxP and SM22-CreKI/Klf4loxP/loxP mice at P14
(n  3). *, p  0.05 compared with control mice. Ab, antibody.
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mice (31). However, it is also possible that we could not detect a
transient change in cellular proliferation in our assays, although
we measured the fraction of Ki-67 positive cells and phospho-
histone H3-positive cells (data not shown) in the hearts of con-
ditional Klf4 knock-out mice and control mice at P28 as well as
E18.5. Studies from a number of laboratories (32, 33), including
our own (12), have shown thatKlf4 can profoundly alter cellular
growth by activating the cyclin-dependent kinase inhibitor,
p21WAF1/Cip1 inmultiple cell types. As such, it is possible that at
least some of the effects of Klf4 deletion in the heart may be
secondary to alterations in cellular proliferation.
Results of dual immunofluorescence studies in Fig. 2G
showed that some of Klf4-positive cells were also positive for
Gata4, which is mainly expressed in cardiomyocytes. However,
some Klf4-positive cells were negative for Gata4, which might
be other cardiac cell types, such as cardiac fibroblasts. To fur-
ther determine the role of Klf4 in the heart, it is interesting to
generate other types of conditional Klf4-deficient mice using
multiple cardiomyocyte-specific Cre recombinase expressing
mouse lines, including MHC-Cremice.
In contrast to the marked effects on cardiac development,
smooth and cardiacmuscle-specific conditionalKlf4 knock-out
mice had no discernible phenotype in SMCs within arteries
such as the coronary artery versus the aorta where SMCs have
distinct embryological origins (34). However, as occurred in the
heart, Klf4 deletion in the present studies would have occurred
after initial differentiation of SMCs, and we cannot rule out a
possible role of Klf4 earlier in SMC development. Consistent
with this possibility, Passman et al. (35) recently demonstrated
high levels of Klf4 expression in Sca1-positive adventitial cells
which can differentiate into vascular SMCs. Indeed, they found
that Klf4 expression was markedly down-regulated when these
cells differentiated into SMCs in vitro, suggesting a possible role
for Klf4 in maintenance of pluripotency and/or self-renewal in
these cells. In addition, we have recently shown that tamoxifen-
induced deletion of the Klf4 gene in mice exhibited delayed
down-regulation of SMCdifferentiationmarkers, but exhibited
subsequent SMC hyperproliferation and enhanced neointimal
formation following vascular injury (12). These results impli-
cate Klf4 as a critical mediator of transitions in SMCphenotype
to a more plastic embryonic state in vivo. However, loss of Klf4
in other cell types might also contribute to the phenotype
observed in tamoxifen-induced conditional Klf4-deficient
mice. Indeed, Klf4 is expressed in aortic endothelial cells and
macrophages and has been shown to play anti-inflammatory
and proinflammatory roles in each cell type, respectively (13,
36). As such, further studies are needed to clearly elucidate the
role of Klf4 in SMC development and phenotypic switching in
vivo. However, given the observed defects in cardiac function
and gene expression, aswell as large reduction in bodyweight in
SM22-CreKI/Klf4loxP/loxP mice, these studies will require
SMC-specific, rather than SMC-selective, conditional Klf4
knock-out mice.
In summary, we provide novel evidence that Klf4 plays a crit-
ical role in late fetal and/or postnatal cardiac development.
Indeed, loss of Klf4 in mouse heart caused decreased cardiac
output, resulting in severe growth retardation and postnatal
death. We also present evidence suggesting that defects in car-
diac function within conditional Klf4 knock-out mice are the
result of reduced expression of multiple cardiac genes. Further
studies are needed to determine the precisemechanisms bywhich
Klf4 regulates cardiac differentiation and maturation during the
postnatal period, aswell as the role ofKlf4 in development of heart
disease in experimental animal models and in humans.
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